In 2021, the U.S. states with the highest death rates from Alzheimer’s disease were Mississippi, Alabama, and Vermont. At that time, the death rate due to Alzheimer’s disease in South Dakota was 44 per 100,000 population. However, the state with the highest total number of deaths due to Alzheimer’s disease that year was California, with 16,911 such deaths.

Alzheimer’s disease among the leading causes of death in the U.S. As of 2021, Alzheimer’s disease was the seventh leading cause of death in the United States. The death rate due to Alzheimer’s disease in the U.S. has more than doubled over the past couple of decades, reaching an estimated 37 deaths per 100,000 population in 2019. Age is the biggest risk factor for Alzheimer’s, so it is no surprise that the death rate from the disease increases significantly with age. For example, in 2021, the Alzheimer’s death rate among those aged 85 years and older was 1,244 per 100,000 population, compared to a rate of 214 per 100,000 population among those aged 75 to 84 years.

How many people in the U.S. have Alzheimer’s disease? It was estimated that in 2020, around 6.1 million people aged 65 years and older in the United States were living with Alzheimer’s disease. This figure is expected to increase to around 8.5 million by the year 2030. A rise in life expectancy and the increasing elderly population go some ways in explaining the increase in Alzheimer's in the United States. However, a growing number of Americans are also living with known modifiable Alzheimer’s risk factors such as high blood pressure, obesity, and diabetes.

In 2022, the mortality rate due to Alzheimer's disease was 36 deaths per 100,000 people. This statistic displays the annual Alzheimer's disease mortality rate in the United States from 2000 to 2022. Scientists believe that early detection of Alzheimer's can be the best way to prevent or slow the course of the disease. Alzheimer’s disease Alzheimer’s disease, a progressive and incurable brain disease, is among the top ten leading causes of death in the U.S. as well as worldwide. Furthermore, over the past two decades, the number of deaths due to Alzheimer’s and other dementias in the United States increased by over 140 percent. As with other dementias, Alzheimer’s commonly affects older individuals, although it can be diagnosed earlier on in life. In the United States, the majority of people with Alzheimer’s disease are over 75 years of age. Initial symptoms include difficulties in memory and mood changes, but the disease gradually progresses to impair communication and judgment, behavioral changes, and deficits in movement and motor skills, such as difficulties with swallowing, which often becomes a contributing cause of death. Care and treatment The cost of care for individuals with Alzheimer’s is expected to increase over the next couple of decades, with costs to Medicare and Medicaid expected to reach 637 billion U.S. dollars by 2050. Due to the increasing burden of Alzheimer’s and other dementias on healthcare and social systems, research into treatment and prevention is a major focus. Several major pharmaceutical companies currently have multiple drugs for Alzheimer’s treatment in various stages of development; other research is focused on identifying early brain changes associated with the disease in order to provide early diagnosis and intervention. Furthermore, personal health strategies include reducing modifiable risk factors commonly associated with cardiovascular health, such as quitting smoking, maintaining a healthy diet, and staying socially, mentally, and physically active.

FOR SINGLE DATA YEARS: Death rates are calculated based on the resident population of the data year involved. For census years, April 1 census counts are used (e.g. 2010). For postcensal years, July 1 estimates from the postcensal Vintage that matches the data year are used (e.g. July 1, 2011 resident population estimates from Vintage 2011 are used as the denominator for 2011rates). For intercensal years, intercensal population estimates are used in rate calculations (e.g. 1991-1999, 2001-2009). Race-specific population estimates for 1991 and later use bridged-race categories.

FOR SINGLE DATA YEARS: Death rates are calculated based on the resident population of the data year involved. For census years, April 1 census counts are used (e.g. 2010). For postcensal years, July 1 estimates from the postcensal Vintage that matches the data year are used (e.g. July 1, 2011 resident population estimates from Vintage 2011 are used as the denominator for 2011rates). For intercensal years, intercensal population estimates are used in rate calculations (e.g. 1991-1999, 2001-2009). Race-specific population estimates for 1991 and later use bridged-race categories.

This statistic shows the percentage changes in selected causes of death due to diseases in the United States, between 2000 and 2022. The number of deaths caused by prostate cancer increased by 7.4 percent during this period. Changes in selected causes of deathThere has been a decrease in the rate of death caused by many diseases, including stroke and heart disease. However, the mortality rate due to Alzheimer’s disease increased by 142 percent from 2000 to 2022. Alzheimer’s disease caused 27.7 deaths per 100,000 population in 2023, making it the sixth leading cause of death in the United States. Mortality rates due to different diseases vary by different factors, including race and ethnicity. For example, cancer is the leading cause of death among Asians and Pacific Islanders in the United States, accounting for 22 percent of total deaths among this population, while heart disease is the leading cause of death among the white population. Ischemic heart disease is the leading cause of death worldwide, accounting for around nine million deaths in 2021. In the early 1900's, the mortality rate was primarily concentrated among people of younger ages, but increasingly, this has shifted to older population groups. In recent years, decreased mortality rates are often linked to improved medical care, such as new developments in medical technologies. Shifts in lifestyle habits such as decreased smoking rates and healthier diets may also attribute to lower mortality rates.

FOR SINGLE DATA YEARS: Death rates are calculated based on the resident population of the data year involved. For census years, April 1 census counts are used (e.g. 2010). For postcensal years, July 1 estimates from the postcensal Vintage that matches the data year are used (e.g. July 1, 2011 resident population estimates from Vintage 2011 are used as the denominator for 2011rates). For intercensal years, intercensal population estimates are used in rate calculations (e.g. 1991-1999, 2001-2009). Race-specific population estimates for 1991 and later use bridged-race categories.

FOR SINGLE DATA YEARS: Death rates are calculated based on the resident population of the data year involved. For census years, April 1 census counts are used (e.g. 2010). For postcensal years, July 1 estimates from the postcensal Vintage that matches the data year are used (e.g. July 1, 2011 resident population estimates from Vintage 2011 are used as the denominator for 2011rates). For intercensal years, intercensal population estimates are used in rate calculations (e.g. 1991-1999, 2001-2009). Race-specific population estimates for 1991 and later use bridged-race categories.

In 2023, there were around 17 deaths per 100,000 population among women in Canada due to Alzheimer's disease. This statistic displays the death rate for Alzheimer's disease in Canada from 2000 to 2023, by gender.

In 2022, there were 3.5 deaths due to Alzheimer's per 100,000 population aged 55 to 64 years. Scientists believe that early detection of Alzheimer's can be the best way to prevent or slow the course of the disease. This statistic shows the Alzheimer's Disease mortality rates from 2000 to 2022 in the United States, by age group.

FOR SINGLE DATA YEARS: Death rates are calculated based on the resident population of the data year involved. For census years, April 1 census counts are used (e.g. 2010). For postcensal years, July 1 estimates from the postcensal Vintage that matches the data year are used (e.g. July 1, 2011 resident population estimates from Vintage 2011 are used as the denominator for 2011rates). For intercensal years, intercensal population estimates are used in rate calculations (e.g. 1991-1999, 2001-2009). Race-specific population estimates for 1991 and later use bridged-race categories.

ObjectivesThis study aims to analyze the prevalence, impact, and disparities of Alzheimer's disease and other dementias (ADRD) among adults aged 65 years and older worldwide, across different regions and countries, spanning the years 1991–2021.MethodsGBD 2021 obtained data on dementia from vital registration systems, published scientific literature and surveys, and data from health-service encounters on deaths, excess mortality, prevalence, and incidence from 1991 to 2021, through systematic review and additional data-seeking efforts. Individuals aged ≥65 years from 21 regions and 204 countries and territories (Global Burden of Disease and Risk Factors Study 2021) from 1991 to 2021 were analyzed. Primary outcomes were ADRD related to aged ≥65 years age-standardized prevalence, deaths, disability-adjusted life years (DALYs), and average annual percentage change (AAPC), and the fractions of these metrics that were attributable to three risk factors (high BMI, high fasting glucose, and smoking) that met GBD.ResultsThe global mortality of ADRD among adults aged ≥65 years increased by 115%, from 6.5 (95% UI 1.5–18) per 100,000 population in 1991 to 14 (95% UI 3.5–37) per 100,000 population in 2021, with an Average Annual Percentage Change (AAPC) of 1.10% (95%CI 0.45%−1.76%). The prevalence of ADRD in adults aged ≥65 years increased by 160% between 1991 and 2021, from 18.7 (95%UI 14.9–23.2) million to 49 (95%UI 38.6–61.2) million. The aged ≥65 years age-standardized prevalence of ADRD in this age group increased from 11,977 (95%UI 9,438–14,935) per 100,000 population in 1991 to 12,124 (95%UI 9,489–15,204) per 100,000 population in 2021. The aged ≥65 years the number of prevalent persons was more significant among females than among males (males: from 6.2 (95%UI 4.8–7.8) million in 1991 to 17.2 (95%UI 13.4–21.6) million in 2021; women: from 12.5 (95%UI 10.0–15.4) million in 1991 to 31.7 (95%UI 25.1–39.6) million in 2021). In 2021, ADRD in adults aged ≥65 years caused 8.02 (95%UI 1.34–22.19) million deaths and 25.38 (95%UI 23.18–71.20) million DALYs attributable to dementia, and high BMI, high fasting glucose, and smoking remained modifiable risk factors in all risk factors.ConclusionsFrom 1991 to 2021, the worldwide prevalence of Alzheimer's disease and other dementias among adults aged 65 and above has increased by 1.6 times, largely driven by the expanding older adults. This escalating trend poses significant challenges to the global healthcare system in terms of both mortality rates and disability-adjusted life years. We recommend that standardized screening programmes be promoted globally, especially in high-risk areas and among high-risk populations, for early detection and intervention of the disease. Secondly, we recommend strengthening the management of risk factor elements.

In 2019, the death rate for Alzheimer's disease among men in the United States aged 65 years and older was around 187 per 100,000 population, compared to a rate of 263 per 100,000 population among women. This statistic shows the death rates for Alzheimer's disease among adults in the United States aged 65 years and older from 2000 to 2019, by gender.

FOR SINGLE DATA YEARS: Death rates are calculated based on the resident population of the data year involved. For census years, April 1 census counts are used (e.g. 2010). For postcensal years, July 1 estimates from the postcensal Vintage that matches the data year are used (e.g. July 1, 2011 resident population estimates from Vintage 2011 are used as the denominator for 2011rates). For intercensal years, intercensal population estimates are used in rate calculations (e.g. 1991-1999, 2001-2009). Race-specific population estimates for 1991 and later use bridged-race categories.

The leading causes of death in the United States are by far cardiovascular diseases and cancer. However, the death rates from these diseases, as well as other leading causes of death, have decreased over the past few decades. The one major exception are deaths caused by Alzheimer’s disease, which have increased significantly. Cardiovascular disease deaths Although cardiovascular diseases are currently the leading cause of death in the United States, the death rate of these diseases has dropped significantly. In the year 1950, there were around *** deaths per 100,000 population due to cardiovascular diseases. In the year 2022, this number was ***** per 100,000 population. Risk factors for heart disease include smoking, poor diet, diabetes, obesity, stress, family history, and age. Alzheimer’s disease deaths While the death rates for cardiovascular disease, cancer, diabetes, and chronic lower respiratory diseases have all decreased, the death rate for Alzheimer’s disease has increased. In fact, from the year 2000 to 2021, the death rate from Alzheimer’s disease rose an astonishing *** percent. This increase is in part due to a growing aging population.

BackgroundThe number of individuals with dementia is increasing, which negatively affects families, communities, and health care systems worldwide. The changes in the incidence of and mortality due to Alzheimer’s disease and other forms of dementia at the national level in China have remained unknown over the past three decades.MethodsFollowing the general analytical strategy used in the Global Burden of Disease Study (GBD) 2019, the age- and sex-specific incidence and mortality rates for dementia in China were analyzed. Trends in the incidence of and mortality due to dementia from 1990 to 2019 were assessed by joinpoint regression analysis. The effects of age, period and cohort on the incidence of and mortality due to dementia were estimated by an age-period-cohort model.ResultsThe age-standardized incidence and mortality rates per 100,000 population were 103.83 (95% UI, 87.93–118.87) and 23.32 (95% UI, 5.66–61.31), respectively, for dementia in 2019. From 1990 to 2019, a significant average annual percentage change (AAPC) in the age-standardized incidence rate was observed in both males [0.49% (95% CI, 0.43–0.55%)] and females [0.31% (95% CI, 0.24–0.38%)], and the age-standardized mortality rate significantly increased in males [0.42% (95% CI, 0.31–0.53%)]. The population aged 55–59 years had the highest AAPC in the incidence of dementia [0.87% (95% CI, 0.81–0.93%)]. The age effect showed that the relative risks (RRs) of incident dementia and dementia-associated mortality increased with age among males and females, and individuals aged 60 years and older had significantly higher RRs. The RR of incident dementia increased with time, and the RR started to substantially increase in 2009. The cohort effect showed that the incidence decreased in successive birth cohorts.ConclusionAlzheimer’s disease and other forms of dementia continue to become more common among males and females in China, and the associated mortality rate in males significantly increased from 1990 to 2019. Early interventions should be implemented to reduce the burden of dementia on individuals at high risk in China.

FOR SINGLE DATA YEARS: Death rates are calculated based on the resident population of the data year involved. For census years, April 1 census counts are used (e.g. 2010). For postcensal years, July 1 estimates from the postcensal Vintage that matches the data year are used (e.g. July 1, 2011 resident population estimates from Vintage 2011 are used as the denominator for 2011rates). For intercensal years, intercensal population estimates are used in rate calculations (e.g. 1991-1999, 2001-2009). Race-specific population estimates for 1991 and later use bridged-race categories.

Data by medical encounter for the following conditions by age, race/ethnicity, and gender:
Alzheimer's Disease
Alzheimer's Disease and Related Dementias (ADRD)
Dementia
Neurocognitive Disorders
Parkinson's Disease

Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.
Blank Cells: Rates not calculated for fewer than 11 events. Rates not calculated in cases where zip code is unknown. Geography not reported where there are no cases reported in a given year. SES: Is the median household income by SRA community. Data for SRAs only.
*The COVID-19 pandemic was associated with increases in all-cause mortality. COVID-19 deaths have affected the patterns of mortality, including those of ADRD conditions.

Data sources: California Department of Public Health, Center for Health Statistics, Office of Health Information and Research, Vital Records Business Intelligence System (VRBIS). California Department of Health Care Access and Information (HCAI), Emergency Department Database and Patient Discharge Database, 2020. SANDAG Population Estimates, 2020 (vintage: 09/2022). Population estimates were derived using the 2010 Census and data should be considered preliminary. Prepared by: County of San Diego, Health and Human Services Agency, Public Health Services, Community Health Statistics Unit, February 2023.

2020 Community Profile Data Guide and Data Dictionary Dashboard: https://public.tableau.com/app/profile/chsu/viz/2020CommunityProfilesDataGuideandDataDictionaryDashboard_16763944288860/HomePage

FOR SINGLE DATA YEARS: Death rates are calculated based on the resident population of the data year involved. For census years, April 1 census counts are used (e.g. 2010). For postcensal years, July 1 estimates from the postcensal Vintage that matches the data year are used (e.g. July 1, 2011 resident population estimates from Vintage 2011 are used as the denominator for 2011rates). For intercensal years, intercensal population estimates are used in rate calculations (e.g. 1991-1999, 2001-2009). Race-specific population estimates for 1991 and later use bridged-race categories.

In 2022, there were ***** deaths caused by Alzheimer's disease per 100,000 population in South Korea. One of several neurodegenerative diseases, it often leads to dementia and is more commonly found in the elderly.

Abstract Background: This study analyzed the causes of death in the Korean population in 2020. Methods: Cause-of-death data for 2020 from Statistics Korea were examined based on the Korean Standard Classification of Diseases and Causes of Death, 7th revision and the International Statistical Classification of Diseases and Related Health Problems, 10th revision. Results: In total, 304,948 deaths occurred, reflecting an increase of 9,838 (3.3%) from 2019. The crude death rate (the number of deaths per 100,000 people) was 593.9, corresponding to an increase of 19.0 (3.3%) from 2019. The 10 leading causes of death, in descending order, were malignant neoplasms, heart diseases, pneumonia, cerebrovascular diseases, intentional self-harm, diabetes mellitus, Alzheimer’s disease, liver diseases, hypertensive diseases, and sepsis. Cancer accounted for 27.0% of deaths. Within the category of malignant neoplasms, the top 5 leading organs of involvement were the lung, liver, colon, stomach, and pancreas. Sepsis was included in the 10 leading causes of death for the first time. Mortality due to pneumonia decreased to 43.3 (per 100,000 people) from 45.1 in 2019. The number of deaths due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was 950, of which 54.5% were in people aged 80 or older. Conclusion: These changes reflect the continuing increase in deaths due to diseases of old age, including sepsis. The decrease in deaths due to pneumonia may have been due to protective measures against SARS-CoV-2. With the concomitant decrease in fertility, 2020 became the first year in which Korea’s natural total population decreased.